Data from EMC - Curated by Toby Galbraith - Last updated 16 March 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Olumiant may be used as monotherapy or in combination with methotrexate.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure


Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

Visit Chronic Spontaneous Urticaria (CSU)


Related Content

More information

Category Value
Agency product number EMEA/H/C/004085
Orphan designation No
Date First Approved 13-02-2017
Type POM
Marketing authorisation holder Eli Lilly Nederland B.V.